Inlay

🔎 Know the Symptoms of Pancreatic Cancer Recently diagnosed with diabetes and not sure why? In some cases, new-onset diabetes can be linked to pancreatic cancer. Learn the 10 warning signs: https://pancreaticcancereurope.eu/wp-content/uploads/2024/04/10WS_en.pdf

Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you. https://bit.ly/4uWZ9C5 #OncSky

In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. Full INDIGO trial results: https://nej.md/4fKYQG4 #EULAR2026

In this issue of Developmental Cell, Wang et al. establish a murine resectable pancreatic ductal adenocarcinoma (PDAC) model and identify circadian re…

Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program.

Screening can help reverse the rising trend of digestive cancers across Europe – but only if it reaches everyone. Zorana Maravic from @digestivecancerseu.bsky.social calls for urgent action to raise awareness, increase uptake & close the access gap: https://bit.ly/4mYFleR #DigestiveHealthMonth

Did you know Gutflix has bookmarks? 🔖 Build your 'study later' list 🔖 Pick up where you left off 🔖 Save what matters to your practice Bookmark your favourite content today: https://gutflix.eu/

Morgen startet die Aktionswoche Alkohol - unterstützt durch die Stabsstelle #Krebsprävention des DKFZ. Sie lädt dazu ein, sich mit #Alkohol und Alkoholkonsum kritisch auseinanderzusetzen. Hier gibt es wissenschaftlich fundierte Informationsmaterialien: t1p.de/80guf @bdb-offiziell.bsky.social

ICYMI: New online! Identifying MASLD patient eligibility for pharmacological therapy: the need to integrate evidence into clinical practice

Nature Reviews Gastroenterology & Hepatology, Published online: 20 May 2026; doi:10.1038/s41575-026-01214-8Metabolic dysfunction-associated steatotic liver disease is a leading cause of chronic liver disease, with rising liver transplantation rates. New therapies such as resmetirom and semaglutide mark a shift in treatment. However, identifying suitable patients remains challenging, requiring integrated approaches combining fibrosis stage, metabolic factors and non-invasive tools in real-world practice.

Same as we reached within #PANCAIM @euprojectpulse.bsky.social project with the #grandchallenge #PANORAMA study! Read our piece in @thelancet.com

A new AI model reliably identifies hidden pancreatic ductal adenocarcinoma on routine CT scans months before the clinical diagnosis of the disease.